Johnson & Johnson Innovative Medicine has appointed Michaela Hagenhofer as General Manager of its commercial operations for Ireland. Michaela will be responsible for leading all aspects of the commercial business in Ireland, focused on driving sustainable business growth through enhanced access to innovative therapies.
Michaela brings a wealth of experience to her new role, having previously served as Commercial Director for Specialty Care at J&J Innovative Medicine in Austria. During her tenure, she achieved consistent business growth across key therapeutic areas including immunology, central nervous system, and cardiopulmonary therapies, driven by a customer-centric approach and a commitment to talent development.
She has dedicated her career to date to the pharmaceutical industry, having previously worked for Takeda, AbbVie and Merck in roles with increased responsibility across many therapy areas including haematology, oncology and gastroenterology.
Johnson & Johnson Innovative Medicine innovates with purpose to lead where medicine is going. Its ambition is to tackle the toughest health challenges, where patient need is highest. Currently, its research and development are focused on the areas of oncology, immunology, neuroscience, cardiopulmonary and specialty ophthalmology, with a commitment to changing the standard of care including evaluation of new medicines and therapeutic interventions that are personalised for optimised clinical outcomes.
Based in Dublin, Michaela is enthusiastic about the opportunities that lie ahead. Commenting on her appointment, Michaela said, “Taking on the role of General Manager for Johnson & Johnson Innovative Medicine Commercial Operations Ireland is an exciting next chapter in my career. As a business, we are committed to leading where medicine is going, identifying the patients with the highest unmet need and developing increasingly personalised care for specific sub-sets of patients. I am committed to continuing to collaborate with our talented team in Ireland to seek timely access to these innovative treatments, working in partnership with the Government, patient groups, the health service, academia and the wider industry to make a tangible difference in the lives of people, health systems and society here.”
With a presence in Ireland since 1981, J&J Innovative Medicine employs over 1,200 dedicated individuals at its two sites in Cork spanning manufacturing and R&D, together with its commercial office in Dublin. The company applies rigorous science with compassion, to confidently address the most complex diseases of our time and unlock the potential medicines of tomorrow. ENDS
ABOUT JOHNSON & JOHNSON
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at https://innovativemedicine.jnj.com/ireland/. Follow us on LinkedIn.
The site you’re being redirected to is an external website where this Privacy Policy does not apply. Please click below to continue to that site.You are now leaving J&J Innovative Medicine Ireland
Janssen Sciences Ireland UC, is a Johnson & Johnson company.
CP-488333 | November 2024